The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Circuits & Cellular Targets for PD’s Symptoms, 2025Role of B2*-Nicotinic Receptors in Parkinson’s Disease Related Circuits and Symptoms
Study Rationale: One pathological hallmark of Parkinson’s disease (PD) is the degeneration of dopamine neurons innervating the striatum. Dopamine loss is associated with several adaptive changes in...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025SUPPLEMENT: IRL757 for the Treatment of Apathy in Parkinson's Disease
Study Rationale: People with PD frequently develop a loss of motivation and initiative. This phenomenon is called apathy and can be a very burdensome symptom of PD, affecting not only the patient but...
-
ASAP CRN Discovery Fellowship 2025, 2026Untangling PINK1–Tau Crosstalk and Co-Morbidity Mechanisms in Parkinson’s Disease
Study Rationale:
Parkinson’s disease is a brain disorder that gets worse over time, causing problems with movement and cognitive abilities. Two key problems are often seen...
-
MJFF Research Grant, 2010Clinical Assessment of Patients with PD Who Underwent DAT Scan and FDG PET at the Early Stages of Their Extra-Pyramidal Disorder as Part of Their Initial Workup
Objective/Rationale:
Ashkenazi Jewish PD patients in Israel have a 14% chance of carrying the G2019S LRRK2 mutation and 18% of carrying mutations in the GBA gene. Little is known on the association... -
Rapid Response Innovation Awards, 2009Plasma Biomarker Screen for Neurodegeneration and Signaling Proteins
Objective/Rationale:
The cells and tissues of the body can “communicate” with one another using small secreted proteins that can be found in the blood. There are several hundred of these cellular... -
Novel Approaches to Drug Discovery for Parkinson's Disease, 2007Fisetin and Derivatives as Neuroprotective Drugs for the Treatment of Parkinson's Disease
Objective/Rationale:
Glutathione (GSH) is an antioxidant produced naturally by cells thereby providing them with a defense against oxidative stress. There is good evidence that GSH levels decrease in...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.